Blood–brain interfaces and cerebral drug bioavailability

• Published in: Revue neurologique 2009-12, Vol.165 (12), p.1029-1038
• Main Authors: Ghersi-Egea, J.-F., Mönkkönen, K.S., Schmitt, C., Honnorat, J., Fèvre-Montange, M., Strazielle, N.
• Format: Article
• Language: English
• Subjects: Adult; Animals; Barrière hémo-encéphalique; Biological Availability; Blood-Brain Barrier - physiology; Blood–brain barrier; Blood–CSF barrier; Brain - growth & development; Brain - physiology; Brain development; Capillaries - physiology; Capillaries - physiopathology; Cerebrospinal Fluid - physiology; Child; Drug Therapy - methods; Développement cérébral; Endothelium, Vascular - physiology; Endothelium, Vascular - physiopathology; Ependyma; Humans; Models, Animal; Multidrug resistance; Nervous System Diseases - drug therapy; Plexus choroïde; Rats; Résistance multiple aux médicaments; Tight Junctions - physiology; Épendyme
• ISSN: 0035-3787
• DOI: 10.1016/j.neurol.2009.09.011

The low cerebral bioavailability of various drugs is a limiting factor in the treatment of neurological diseases. The restricted penetration of active compounds into the brain is the result of the same mechanisms that are central to the maintenance of brain extracellular fluid homeostasis, in particular from the strict control imposed on exchanges across the blood–brain interfaces. Direct drug entry into the brain parenchyma occurs across the cerebral microvessel endothelium that forms the blood–brain barrier. In addition, local drug concentration measurements and cerebral imaging have clearly shown that the choroid plexuses – the main site of the blood–cerebrospinal fluid (CSF) barrier – together with the CSF circulatory system also play a significant role in setting the cerebral bioavailability of drugs and contrast agents. The entry of water-soluble therapeutic compounds into the brain is impeded by the presence of tight junctions that seal the cerebral endothelium and the choroidal epithelium. The cerebral penetration of many of the more lipid-soluble molecules is also restricted by various classes of efflux transporters that are differently distributed among both blood–brain interfaces, and comprise either multidrug resistance proteins of the ATP-binding cassette superfamily or transporters belonging to several solute carrier families. Expression of these transporters is regulated in various pathophysiological situations, such as epilepsy and inflammation, with pharmacological consequences that have yet to be clearly elucidated. As for brain tumour treatments, their efficacy may be affected not only by the intrinsic resistance of tumour cells, but also by endothelial efflux transporters which exert an even greater impact than the integrity of the endothelial tight junctions. Relevant to paediatric neurological treatments, both blood–brain interfaces are known to develop a tight phenotype very early on in postnatal development, but the developmental profile of efflux transporters still needs to be assessed in greater detail. Finally, the exact role of the ependyma and pia-glia limitans in controlling drug exchanges between brain parenchyma and CSF deserves further attention to allow more precise predictions of cerebral drug disposition and therapeutic efficacy. La faible biodisponibilité cérébrale de nombreux médicaments est un des facteurs qui limitent l’efficacité des traitements neurologiques. Elle résulte des mêmes mécanismes qui assurent le mainti